Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil

Drug Delivery

Volumn 17, Issue 8, 2010, Pages 561-572

  Yadav, Awesh K ^a   Agarwal, Abhinav ^a   Rai, Gopal ^a   Mishra, Pradeep ^b   Jain, Sanyog ^c   Mishra, Anil K ^d   Agrawal, Himanshu ^e   Agrawal, Govind P ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b GLA UNIVERSITY   (India)

^c NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^d INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^e M S UNIVERSITY OF BARODA   (India)

Author keywords

5 fluorouracil; Cancer; Hyaluronic acid; PLGA nanoparticles; Targeted delivery

Indexed keywords

COPOLYMER; FLUOROURACIL; HYALURONIC ACID; MACROGOL; NANOPARTICLE; POLYGLACTIN; TECHNETIUM 99M; TETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER INHIBITION; CELL LINE; CELL PROLIFERATION; CONJUGATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RETENTION; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; FOURIER TRANSFORMATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE LEVEL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; X RAY DIFFRACTION;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HYALURONIC ACID; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TOXICITY TESTS; X-RAY DIFFRACTION;

EID: 77957740499     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.500635     Document Type: Article

References (53)

1. Agarwal, A., Asthana, A., Gupta, U., Jain, N.K. (2008b). Tumour and dendrimers: a review on drug delivery aspects. JPP. 60:671-88.
2. Agarwal, A., Gupta, U., Asthana, A., Jain, N.K. (2009). Dextran conjugated dendritic nanoconstructs as potential vectors for anticancer agent. Biomaterials. 30:3588-96.
3. Agarwal, A., Saraf, S., Asthana, A., Gupta, U., Gajbhiye, V, Jain, N.K. (2008a). Ligand based dendritic sytems for tumor targeting. Int J Pharm. 350:3-13.
4. Anghileri, L.J. (1976). In vivo synthesis of acid mucopolysaccharides by Ehrlich ascites tumor cells. J Cancer Res Clin Oncol. 88:17-24.
5. Aranda, E., Diaz-Rubio, E., Cervantes, A., Anton-Torres, A., Carrato, A., Massuti, T., Tabernero, J.M., Sastre, J., Tres, A., Aparicio, J., Lopez-Vega, J.M., Barneto, I., Garcia-Conde, J. (1998). Randomized trial comparing monthly low-dose leucovorin and fuorouracil bolus with weekly high-dose 48-hour continuous-infusion fuorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Terapy (TTD) study. Ann Oncol. 9:727-31.
6. Asplund, T., Heldin, P. (1994). Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 54:4516-23.
7. Bhadra, D., Bhadra, S., Jain, S., Jain, N.K. (2003). PEGylated dendritic nanoparticulate carrier of fuorouracil. Int J Pharm. 257:111-24.
8. Cho, H., Chung, D., Jeongho, A. (2004). Poly(D,L-lactide-ran- εcaprolactone)-poly (ethylene glycol)-poly(D,L-lactide-ran- εcaprolactone) as parenteral drug-delivery systems. Biomaterials. 25:3733-42.
9. Culty, M., Nguyen, H.A., Underhillm, C.B. (1992). Te hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol. 116:1055-62.
10. Diasio, R.B., Lu, Z. (1994). Dihydropyrimidine dehydrogenase activity and fuorouracil chemotherapy. J Clin Oncol. 12:2239-42.
11. Dubernet, C. (1995). Termoanalysis of microspheres. Termochim Acta. 248:259-69.
12. Gamelin, E.C., Danquechin-Dorval, E.M., Dumesnil, Y.F., Maillart, P.J., Goudier, M.J., Burtin, P.C., Delva, R.G., Lortholary, A.H., Gesta, P.H., Larra, F.G. (1996). Relationship between 5-fuorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy contain-ing 5-FU. Cancer 77:441-51.
13. Gref, R., Couvreur, P., Barratt, G., Mysiakine, E. (2003). Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials. 24:4529-37.
14. Hans, M., Shimoni, K., Danino, D., Siegel, S.J., Lowman, A. (2005). Synthesis and characterization of mPEG-PLA prodrug micelles. Biomacromolecules. 6:2708-17.
15. He, Y.C., Chen, J.W., Cao, J., Pan, D.Y., Qiao, J.G. (2003). Toxicities and therapeutic efect of 5-fuorouracil controlled release implant on tumor-bearing rats. World J Gastroenterol. 9:1795-98.
16. Iba, T., Yagi, Y., Kidokoro, A., Fukunaga, M., Momose, F., Nagakari, K. (1997). Intermittent low-dose cisplatin infusion as a possible modulator of 5-fuorouracil. Int J Clin Oncol. 2:197-201.
17. Jeon, H., Jeong, Y., Jang, M., Park, Y., Nah, J. (2000). Efect of solvent on the preparation of surfactant-free poly (D,L-lactideco-glycolide) nanoparticles and norfoxacin release characteristics. Int J Pharm. 207:99-108.
18. Lee, J.S., Chae, G.S., An, T.K., Khang, G. (2003). Preparation of 5-fuor-ouracil-loaded poly(L-lactide-co-glycolide) wafer and evaluation of in vitro release behavior. Macromol Res. 11:183-88.
19. Lesley, J., Hascall, V.C., Tammi, M., Hyman, R. (2000). Hyaluronan binding by cell surface CD44. J Biol Chem. 275:26967-75.
20. Li, Y.P., Ogris, M., Wagner, E., Pelisek, J., Rufer, M. (2003). Nanoparticles bearing polyethylene glycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. Int J Pharm. 259:93-101.
21. 99mTc) radiolabelled liposomes. J Microencap. 6:105-13.
22. Luo, Y., Kirker, K.R., Prestwich, G.D. (2000). Cross-linked hyaluronic acid hydrogel flms: new biomaterials for drug delivery. J Control Rel. 69:169-84.
23. 125I-labelled polyamidoamine dendrimers in vivo. J Contr Rel. 65:133-48.
24. Miglietta, A., Cavalli, R., Bocca, C., Gabriel, L., Gasco, M.R. (2000). Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm. 210:61-7
25. Mo, Y., Lim, LY. (2005). Paclitaxel-loaded PLGA nanoparticles: poten-tiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Rel 108:244-62.
26. Mohanraj, V.J., Chen, Y. (2006). Nanoparticles-a review. TJPR. 5:561-73.
27. Mu, L., Feng, S.S. (2002). Vitamin E TPGS used as emulsifer in the solvent evaporation/extraction technique for fabrication of poly-meric nanospheres for controlled release of paclitaxel. J Contr Rel. 80:129-44.
28. Naor, D., Nedvetzki, S., Golan, I., Melnik, L., Faitelson, Y. (2002). CD44 in cancer. Crit Rev Clin Lab Sci, 39:527-79.
29. Nasongkla, N., Shuai, X., Ai, H., Weinberg, B.D., Pink, J., Boothman, D.A., Gao, J. (2004). cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed. 43:6323-27.
30. Panyam, J., Labhasetwar, V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 55:329-47.
31. Park, E.K., Lee, S.B., Lee, Y.M. (2005). Preparation and characterization of methoxy poly-(ethylene glycol)/poly (ε-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specifc folate-mediated targeting of anticancer drugs. Biomaterials. 26:1053-61.
32. Peer, D., Margalit, R. (2004). Tumor-targeted hyaluronan nanolipo-somes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia. 6:343-53.
33. Peracchia, M.T., Gref, R., Minamitake, Y., Domb, A., Lotan, N., Langer, R. (1997). PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: investigation of their drug encapsulation and release characteristics. J Control Release. 46:223-31.
34. Perez, C., Sanchez, A., Putnam, D., Ting, D., Langer, R., Alonso, M.J. (2001). Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Contr Rel. 75:211-24.
35. Ratnam, M., Hao, H., Zheng, X., Wang, H., Qi, H., Lee, R., Pan, X. (2003). Receptor induction and targeted drug delivery: a new antileukemia strategy. Expert Opin Biol Ter. 3:563-74.
36. Reddy, J.A., Dean, D., Kennedy, M.D., Low, P.S. (1999). Optimization of folate conjugated liposomal vectors for folate receptor-mediated gene therapy. J Pharm Sci. 88:1112-8.
37. 99mTc] technetium-labeled liposomes in normal and tumour-bearing rats. Biochem Soc Trans. 5:220-9.
38. Schilsky, R.L., Hohneker, J., Ratain, M.J., Janisch, L., Smetzer, L., Lucas, V.S., Khor, S.P., Diasio, R., Von Hof, D.D., Burris, H.A. (1998). 3rd Phase I clinical and pharmacologic study of enilu-racil plus fuorouracil in patients with advanced cancer. J Clin Oncol. 16:1450-7.
39. Shenoy, D., Little, S., Langer, R., Amiji, M. (2005). Poly (ethylene oxide)-modifed poly (β-amino ester) nanoparticles as a pH-sen-sitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm Res. 22:2101-14.
40. Shenoy, D.B., Amiji, M.M. (2005). Poly (ethylene oxide)-modifed poly (epsilon caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm. 293:261-70.
41. Shirasaka, T., Yamamitsu, S., Tsuji, A., Terashima, M., Hirata, K. (2000). Conceptual changes in cancer chemotherapy-biochemical mod-ulation of 5-FU. Gan To Kagaku Ryoho. 27:832-45.
42. Shuai, X., Ai, H., Nasongkla, N., Kim, S., Gao, J. (2004). Micellar carriers based on block copolymers of poly (ε-caprolactone) and poly (ethylene glycol) for doxorubicin delivery. J Control Rel. 98:415-26.
43. Singhai, A.K., Jain, S., Jain, N.K. (1997). Evaluation of aqueous suspen-sion of ketoprofen. Pharmazie. 52:149-51.
44. Swayam, P., Labhasetwar, V. (2004). Critical determinants in PLGA/PLA nanoparticles-mediated gene expression. Pharm Res. 21:354-64.
45. Wang, C., Tor, A.D., Moore, D.H., Zhao, Y., Kerschmann, R., Stern, R., Watson, P.H., Turley, E.A. (1998). Te overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signalling, cor-relates with over-expression of mitogenactivated protein kinase and is a signifcant parameter in breast cancer progression. Clin Cancer Res. 4:567-76.
46. Xu, Z., Gu, W., Huang, J., Sui, H., Zhou, Z., Yang, Y., Yan, Z., Li, Y. (2005). In vitro and in vivo evaluation of actively targetable nano-particles for paclitaxel delivery. Int J Pharm. 288:361-8.
47. Yadav, A.K., Mishra, P., Mishra, A.K., Mishra, P., Jain, S., Agrawal, G.P. (2007). Development and characterization of hyaluronic acid-an-chored PLGA nanoparticulate carriers of doxorubicin. Nanomed Nanotechnol Biol Med. 3:246-57.
48. Yuan Li, W.G., Li, Z.S., Zhang, S.H., Sun, Y.J., Hu, P.Z., Wang, X.M., Huang, Y., Si, S.Y., Zhang, X.M., Sui, Y.F. (2009). Te antitu-mor immune responses induced by nanoemulsion-encapsu-lated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol Immunother. 58:201-8.
49. Yun, Y.H., Goetz, D.J., Yellen, P., Chen, W. (2004). Hyaluronan micro-spheres for sustained gene delivery and site-specifc targeting. Biomaterials. 25:147-57.
50. Zalipsky, S., Gilon, C., Zilkha, A. (1983). Attachment of drugs to poly-ethylene glycols. Eur Polym J. 19:1177-83.
51. Zambaux, M.F., Bonneaux, F., Gref, R., Dellacherie, E., Vigneron, C. (2001). Protein C-loaded monomethoxypoly(ethylene oxide)-poly(lactic acid) nanoparticles. Int J Pharm. 212:1-9.
52. Zeng, C., Toole, B.P., Kinney, S.D., Kuo, J.W., Stamenkovic, I. (1998). Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer. 77:396-401.
53. Zhang, Y., Guo, L., Roeske, R.W., Antony, A.C., Jayaram, H.N. (2004). Pteroyl-γ-glutamate-cysteine synthesis and its application in folate receptor-mediated cancer cell targeting using folate-tethered liposomes. Anal Biochem. 332:168-77.